Sanofi (SNY) Exercises License Extension Option to Nurix’s (NRIX) STAT6 Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Tanker struck by projectile in Strait of Hormuz
Leerink Partners Reiterates Market Perform Rating on Nurix (NRIX)
June 2, 2025 11:14 AM EDTLeerink Partners analyst Faisal Khurshid reiterated a Market Perform rating and $16.00 price target on Nurix (NASDAQ: NRIX).
The analyst comments "Bottom Line: This morning NRIX announced that partner SAN FP (OP, Risinger) exercised their option to license NRIX's STAT6 program, including development candidate NX-3911. We believe NRIX's STAT6 program has been seen as an interesting... More
